Post-earnings recap
Reported
Wed, Jul 29, 2026
EPS actual
$-1.10
EPS est.
$-1.21
EPS surprise
+9.09%
1-day move
-1.27%
Viking Therapeutics reported a wider-than-expected loss per share but did not provide revenue figures or guidance. The stock reacted negatively, declining by 1.27%, likely reflecting investor concerns about the lack of revenue information and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.10 | N/A | +9.09% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.
Viking Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metabolic and endocrine disorders. With a market cap of $4 billion, its work is significant in the health care sector, particularly as demand for effective treatments in these areas continues to grow.
Last quarter
In Q1 2026, Viking reported an EPS of -$1.37, which was significantly worse than the expected -$0.95, leading to a 3.27% drop in stock price the following day. The company has not provided specific revenue figures, making it difficult to gauge overall performance.
EPS beat streak
1Q
EPS beat rate
25%
Avg EPS surprise
-21.04%
Avg 1-day reaction
-0.48%
Overall, expectations are mixed for Viking's upcoming earnings report, especially given the recent history of EPS misses. Investors are likely to be cautious, considering the company's track record of disappointing results.
Bull case
If Viking can show a smaller loss than expected or even a surprise in revenue, it could signal that their therapies are gaining traction, leading to a positive market reaction.
Bear case
On the other hand, if the company continues to miss EPS expectations, it may raise concerns about its financial health and ability to deliver on its promises, potentially leading to further declines in stock price.
The print will turn on these.
Q1
What will be the reported EPS for Q2-2026?
Given the company's recent history of EPS misses, this number will be critical to gauge investor sentiment and market reaction.
Q2
Is there any update on revenue generation from ongoing trials?
Any positive news on revenue could indicate that Viking's therapies are progressing well, which would be a key driver for stock performance.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±3.5%
Why consensus could be wrong
The Street may be overly pessimistic about Viking's ability to recover, especially if they can show any signs of narrowing losses or revenue generation.
Supporting evidence
Options are pricing a 26% move, indicating expectations for significant volatility, which may not align with the actual performance.
The historical average move has been only around 2.79%, suggesting that the current options pricing could be overestimating potential outcomes.
Key risk
If EPS comes in better than -$1.00, it could shift sentiment dramatically.
Pre-commit to what would confirm each case.
This quarter's performance is critical as investors are looking for signs of recovery after several disappointing earnings reports.
Bull confirmed if
A reported EPS loss of less than -$1.00 would indicate a potential turnaround in performance.
Bear confirmed if
An EPS loss greater than -$1.50 would confirm ongoing struggles and likely lead to further stock declines.
What the market is pricing for the move.
Implied Move
±26.04%
Historical Avg
±2.7%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±26.0% while VKTX has averaged ±2.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
44.1%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
60.60%
of float
Insider
2.84%
of float
Holders
572
institutions
Top Holders· as of Jun 2026
FMR, LLC
6,335,756 sh · $180.8M
5.03%
5.2%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Viking beats expectations, history suggests a potential average move of around -2.42% the following day, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may react mildly, reflecting ongoing investor caution.
Miss
If Viking misses expectations again, the average move suggests a potential decline of around +0.01%, indicating market disappointment.
The lines on the call that would change the story.
Blackrock Inc.
6,189,649 sh · $176.7M
4.91%
-10.0%
State Street Corporation
5,606,394 sh · $160.0M
4.45%
27.6%
Vanguard Capital Management LLC
5,053,663 sh · $144.2M
4.01%
0.8%
Vanguard Portfolio Management LLC
4,484,263 sh · $128.0M
3.56%
0.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.